BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » placental » Page 3

Pluristem Launches Co-CEO Structure and Appoints New CFO

March 29, 2017 By Cade Hildreth (CEO) Leave a Comment

Pluristem Co-CEO and CFO
  • Yaky Yanay appointed Co-Chief Executive Officer to serve together with Co-Chief Executive Officer Zami Aberman
  • Erez Egozi appointed as Chief Financial Officer

[Read more…]

Filed Under: Stem Cells Tagged With: MSC, placental, Pluristem

Placental-Derived Allogeneic Stem Cells Meet the Needs of the Market and the Patient

March 13, 2017 By Cade Hildreth (CEO) Leave a Comment

Pluristem - PLX Placental Stem Cells

As an increasing number of stem cell therapies advance through clinical trials, the healthcare industry’s focus comes to looking at which cells, allogeneic or autologous, are more likely to be commercially feasible. Proving safety and efficacy for a specific indication is a large enough challenge for any treatment, but for stem cell therapies in particular, commercial viability may be just as big a hurdle.

Pluristem Therapeutics Israel-based Pluristem Therapeutics (NASDAQ:PSTI), may be the only stem cell company that can mass produce immune-privileged allogeneic cells at a scale and price that not only makes them commercially viable, but moreover makes stem cell therapy a preferred method of treatment for patients and payors alike. A proprietary 3D stem cell expansion technology which uses placental-derived cells is the key. [Read more…]

Filed Under: Stem Cells Tagged With: news, placental, Pluristem

Top 10 Quotes from the Perinatal Stem Cell Society Conference 2016

March 4, 2016 By Cade Hildreth (CEO) 1 Comment

Over the past three days, dozens of world renowned speakers have presented their latest findings at the Perinatal Stem Cell Society Conference 2016, hosted by Kyle Cetrulo of Auxocell Laboratories and the Perinatal Stem Cell Society (IPLASS).

To capture the best moments from the conference, below are the top 10 quotes from the event, which was hosted at Aspen Meadows Resort in Aspen, CO, over March 2-4, 2016.

I took the image above as we were landing in Aspen. You can see our full photo album from the event on Flickr, featuring presenters, sponsors, and more.

To get live updates from the event, connect with me on Twitter (@StemCellMarket) or follow the hashtag #Perinatal. Enjoy! [Read more…]

Filed Under: HSCs, MSCs, Stem Cells Tagged With: amniotic, conference, cord blood, cord tissue, perinatal, placental, stem cells

Interview with Dr. Racheli Ofir, VP of Research & Intellectual Property at Pluristem Therapeutics

February 22, 2016 By Cade Hildreth (CEO) 1 Comment

Bioreactor Clean Room at Pluristem Therapeutics

Pluristem TherapeuticsI had the honor of interviewing Dr. Racheli Ofir, Vice President (VP) of Research & Intellectual Property at Pluristem Therapeutics. Pluristem is a clinical-stage biotechnology company that uses placental cells and a proprietary, three-dimensional technology platform to develop cell therapies for a broad range of diseases.

The company is at the forefront of placental-based cell therapy applications. In addition to other accomplishments, the company is now preparing for a proposed Phase III trial of its PLX-PAD cells in the treatment of critical limb ischemia (CLI).

Interview with Dr. Racheli Ofir, VP of Research & IP at Pluristem Therapeutics

Racheli Ofir, VP Research & Intellectual Property at Pluristem Therapeutics
Dr. Racheli Ofir

Cade Hildreth: What is your background and how did you get involved with Pluristem?

Dr. Racheli Ofir:  I did my PhD and post-doc in cellular and developmental biology at the Technion in Haifa. I joined Pluristem 9 years ago and am responsible for the research activity of the company including efficacy and safety studies of Pluristem placenta-derived cells, as well as revealing the underlying mechanism of action of the cells. [Read more…]

Filed Under: Cell Therapy, Interviews, MSCs Tagged With: cell therapy, Dr. Racheli Ofir, interview, placental, Pluristem Therapeutics

Human Longevity, Inc. to Expand Reach into Neonatal & Maternal Health Markets by Acquiring Celgene Owned LifebankUSA

January 28, 2016 By Cade Hildreth (CEO) Leave a Comment

Human Longevity, Inc. to Expand Reach into Neonatal & Maternal Health Markets by Acquiring Celegene Owned LifebankUSA

In major news released today, Human Longevity, Inc. (HLI) announced that is is acquiring LifebankUSA, a cord blood, placental blood, and tissue bank owned by Celgene Cellular Therapeutics.

Based in San Diego, CA, Human Longevity, Inc. is an innovative company that specializes in the use of whole genome sequence analysis, clinical imaging, and machine learning to extend health across a longer human lifespan. LifebankUSA, based in Cedar Knolls, NJ, is the “the only company that offers cord blood, placenta blood and tissue banking – and the first to release placenta-derived stem cells for a successful transplant.” Celgene Cellular Therapeutics (CCT), the parent company of LifeBankUSA, specializes in cell therapy and regenerative medicine products, using LifeBankUSA to source its cell therapy, organ and tissue products, several of which are now being explored in clinical trials (PDA001, PDA002, and others).

The move will position Human Longevity, Inc. to offers its newborn genome sequencing product in combination to its newly acquired stem cell banking services.
[Read more…]

Filed Under: Cord Blood, HSCs, MSCs, Press Releases, Stem Cells Tagged With: CBR, cord blood, cord tissue, Human Longevity Inc., placental, stem cells, viacord

  • « Previous Page
  • 1
  • 2
  • 3

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    Rated 0 out of 5
    $297
  • U.S. Cord Blood Banking Survey Cord Blood Banking Survey of U.S. Parents [2017]
    Rated 0 out of 5
    $197
  • Exosome Companies 2020 Global Database of Exosome Companies
    Rated 0 out of 5
    $149 $97
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.